Although the number of assessable CD4+ and CD8+ T cells in each healthy donor and glioblastoma patient prevented us from examining changes in direct TIM-3:BAT3 interaction, our data are consistent with these reports, suggesting that percentage of TIM-3 positivity and downstream function is enhanced due to less BAT3 expression (and presumably reduced TIM-3 association). This evidence concerns the gene CD8A and glioblastoma.